Plasma Renin Activity: What This Test Actually Measures (And Why It Matters for Women)

What Plasma Renin Activity Actually Measures

Plasma renin activity does not measure the concentration of renin protein directly. Instead, it measures the rate at which renin cleaves angiotensinogen into angiotensin I, reported in nanograms of angiotensin I produced per milliliter of plasma per hour (ng/mL/hr). That enzyme-rate framing is why the test is called "activity" and not simply "renin level." A separate assay, direct renin concentration (DRC), measures the protein quantity rather than its function. The two tests are not interchangeable, and many U.S. Centers still use PRA for primary aldosteronism screening because the Endocrine Society's 2016 clinical practice guideline was written around PRA-based aldosterone-to-renin ratios (ARR).

The Renin-Angiotensin-Aldosterone System in Brief

Renin originates in juxtaglomerular cells of the kidney. When blood pressure drops, sodium falls, or the sympathetic nervous system fires, those cells release renin. Renin converts angiotensinogen (made in the liver) to angiotensin I. Angiotensin-converting enzyme (ACE) then converts angiotensin I to angiotensin II, which drives blood pressure up by constricting arteries and signaling the adrenal cortex to release aldosterone. Aldosterone causes the kidneys to retain sodium and excrete potassium. The whole cascade is called the renin-angiotensin-aldosterone system (RAAS). PRA is the upstream throttle on that entire chain.

Why the Rate Matters More Than the Number Alone

A PRA of 0.3 ng/mL/hr looks low in isolation. Paired with an aldosterone of 25 ng/dL, it produces an ARR of 83, which is highly suggestive of primary aldosteronism. The same PRA of 0.3 paired with an aldosterone of 3 ng/dL is completely unremarkable. The Endocrine Society guideline recommends using an ARR cutoff of 30 (with aldosterone in ng/dL and PRA in ng/mL/hr) as a positive screening result, though individual lab thresholds vary. This is why your PRA result should never arrive in your inbox without its aldosterone partner.

Normal Plasma Renin Activity Ranges

Normal values depend on body position, sodium status, time of day, and the assay used by the specific laboratory. Reference ranges from Mayo Clinic Laboratories list approximately 0.5 to 4.0 ng/mL/hr for adults in the upright position after two hours of ambulation on an average-sodium diet. Supine values are lower, typically 0.2 to 1.6 ng/mL/hr.

How Position and Sodium Change the Number

Sodium depletion stimulates renin release. Sodium loading suppresses it. A low-sodium diet for several days before the test can double or triple PRA. Standardized testing protocols ask patients to maintain their usual sodium intake (roughly 3 to 5 grams of sodium daily) for at least three days beforehand, and to be upright for two hours before the blood draw. A 2020 review in the Journal of Hypertension confirmed that failure to standardize posture introduces errors large enough to reclassify a result from suppressed to borderline.

Medications That Shift PRA

| Drug class | Effect on PRA | |---|---| | ACE inhibitors / ARBs | Raise PRA (preferred to hold for 2 weeks before testing) | | Beta-blockers | Suppress PRA (hold 2 weeks if possible) | | Spironolactone / eplerenone | Raise PRA substantially (hold 4 weeks) | | Combined oral contraceptives | Suppress PRA via estrogen effect | | Diuretics (loop, thiazide) | Raise PRA | | NSAIDs | Suppress PRA | | Direct renin inhibitors (aliskiren) | Suppress PRA |

When medications cannot be held safely, the result must be interpreted in that context. Your clinician should document the medication status on the lab requisition.

Women-Specific Physiology: How Hormones Change PRA

This is where most general lab guides fall short. PRA in women is not a static number. It shifts with the menstrual cycle, hormonal contraception, pregnancy, and menopause in ways that change what "normal" means for you at a given moment.

The Menstrual Cycle

Estrogen stimulates hepatic synthesis of angiotensinogen, the substrate renin acts on. Higher angiotensinogen means more substrate available, which can influence apparent PRA. A study in Hypertension (2004) demonstrated that angiotensinogen concentrations are measurably higher in the luteal phase compared with the follicular phase. The clinical significance is modest in healthy women with normal cycles, but it is a real physiological variable that matters when results land near a cutoff.

Oral Contraceptives and Hormonal Contraception

Combined oral contraceptives (COCs) containing ethinyl estradiol raise angiotensinogen. The resulting increase in angiotensin II feeds back to suppress renin release, pushing PRA down. Research published in the American Journal of Hypertension showed that women on high-estrogen pills had significantly lower PRA than non-users, with the magnitude of suppression correlating with estrogen dose. This is clinically important: a woman screened for primary aldosteronism while on a COC may have artificially suppressed PRA, inflating her ARR and producing a false-positive screen. Ideally, testing should be deferred until at least four weeks after stopping estrogen-containing contraception, though this is not always practical. Progestin-only methods (mini-pill, hormonal IUD, implant) have a much smaller effect on PRA.

Postmenopause

After menopause, circulating estrogen falls, and with it, hepatic angiotensinogen production drops. A 2019 analysis in Menopause found that postmenopausal women not using hormone therapy had lower baseline PRA values than age-matched premenopausal women. Women on oral menopausal hormone therapy (particularly estradiol taken orally rather than transdermally) show partial restoration of angiotensinogen and some suppression of PRA, mirroring the COC effect. Transdermal estradiol has a much smaller effect on hepatic protein synthesis and therefore has a smaller impact on PRA, which is one reason transdermal routes are preferred when blood pressure management is a concern.

High Plasma Renin Activity: What It Means

A PRA above the upper reference limit (roughly above 4.0 ng/mL/hr upright) suggests the kidneys are sensing real or perceived low perfusion and are responding appropriately, or there is autonomous renin production. High PRA with high aldosterone points toward secondary hyperaldosteronism. High PRA with normal or low aldosterone points toward a different mechanism of hypertension.

Common Causes of High PRA in Women

• Renal artery stenosis (the classic cause of renovascular hypertension; more common with fibromuscular dysplasia in younger women than with atherosclerosis)
• True volume depletion (blood loss, excessive diuresis, poor oral intake)
• Heart failure or cirrhosis (effective arterial underfilling)
• Renin-secreting tumor (rare)
• Medication effect (ACE inhibitors, ARBs, diuretics, spironolactone)
• Addison's disease / adrenal insufficiency
• Bartter syndrome or Gitelman syndrome (inherited tubular disorders; Gitelman affects women and men equally but presents in young adults and is frequently missed)

Fibromuscular dysplasia (FMD) deserves specific mention here. The U.S. Registry for Fibromuscular Dysplasia reported that over 90% of cases occur in women, with a mean age at diagnosis in the early 50s. FMD causes renal artery narrowing that elevates PRA and produces difficult-to-control hypertension. A young or middle-aged woman with new-onset hypertension and a high PRA should prompt imaging of the renal arteries.

Secondary Hyperaldosteronism

When both PRA and aldosterone are high, the body's renin signal is driving the aldosterone rise appropriately. The ARR is typically below 20 in secondary hyperaldosteronism. Conditions like heart failure, nephrotic syndrome, cirrhosis, and renal artery stenosis all cause this pattern.

Low Plasma Renin Activity: What It Means

Low PRA (below 0.5 ng/mL/hr upright, or per your lab's lower reference limit) with a simultaneously elevated aldosterone is the biochemical signature of primary hyperaldosteronism (also called Conn's syndrome). Primary aldosteronism affects an estimated 5 to 10% of all people with hypertension, making it the most common form of secondary hypertension, and it is substantially under-diagnosed. Women with treatment-resistant hypertension, hypokalemia, adrenal incidentaloma, or early-onset hypertension should be screened.

Primary Hyperaldosteronism

In primary hyperaldosteronism, an adrenal adenoma or bilateral adrenal hyperplasia secretes aldosterone independently of RAAS control. The high aldosterone suppresses RAAS through normal feedback loops, producing the characteristic low-PRA/high-aldosterone pattern. The ARR exceeds 30 ng/dL per ng/mL/hr (using the Endocrine Society's recommended threshold), and confirmatory testing (oral sodium loading, saline infusion, fludrocortisone suppression, or captopril challenge) follows a positive screen.

PCOS and Low-Renin Hypertension

Women with PCOS represent a group where RAAS interpretation requires extra care. Hyperinsulinemia in PCOS can independently stimulate aldosterone secretion through non-RAAS mechanisms and may reduce renin generation. A 2021 study in the Journal of Clinical Endocrinology and Metabolism showed that women with PCOS had measurably higher aldosterone-to-renin ratios compared with body-mass-index-matched controls, even in the absence of frank primary aldosteronism. This suggests that PCOS-related metabolic dysregulation creates a low-renin, relatively high-aldosterone state that can mimic early primary aldosteronism on screening. Women with PCOS who have hypertension deserve a carefully timed, medication-adjusted PRA and ARR before assuming the diagnosis is essential hypertension.

Other Causes of Low PRA

• Primary aldosteronism (adenoma or bilateral hyperplasia)
• Apparent mineralocorticoid excess (licorice ingestion, 11-beta-HSD2 deficiency)
• Cushing's syndrome (excess cortisol activates mineralocorticoid receptor)
• Deoxycorticosterone-producing tumors (very rare)
• Chronic kidney disease (damaged juxtaglomerular apparatus)
• Advanced age
• Beta-blocker or NSAID use

Pregnancy and PRA: A Completely Different Physiology

Plasma renin activity during pregnancy is not comparable to non-pregnant ranges. Full stop. Pregnancy induces one of the most dramatic RAAS activations in human physiology.

First Trimester Through Delivery

By the end of the first trimester, estrogen-driven increases in angiotensinogen have already begun. PRA rises progressively and may reach two to four times the non-pregnant reference range by the third trimester. This is appropriate and necessary: the RAAS expansion supports the 40 to 50% increase in plasma volume that sustains the placenta. Aldosterone also rises, in parallel, to retain sodium and support volume expansion. The ARR may therefore not be a reliable diagnostic tool during pregnancy, and ACOG and the Endocrine Society do not recommend routine screening for primary aldosteronism during pregnancy outside of highly specialist settings.

Preeclampsia and RAAS Disruption

Preeclampsia involves abnormal placentation and endothelial dysfunction that paradoxically blunts the normal RAAS rise. A 2015 analysis published in Hypertension demonstrated that women who developed preeclampsia had lower PRA values in early pregnancy compared with normotensive pregnant women, suggesting that impaired RAAS activation may be part of the preeclamptic phenotype rather than its consequence. This is an area of active research, not yet clinical practice, but it positions PRA as a potential early biomarker in high-risk pregnancies.

Postpartum

PRA returns toward non-pregnant ranges within days to weeks after delivery. Breastfeeding mothers should note that the RAAS remains modestly activated during lactation. Testing for primary aldosteronism should ideally be deferred until at least three months postpartum, after weaning, to avoid pregnancy-associated physiological shifts confounding the result.

Medications Used in RAAS-Related Conditions During Pregnancy

ACE inhibitors and ARBs are contraindicated in pregnancy. The FDA classifies ACE inhibitors as teratogenic in the second and third trimesters, with documented fetal renal tubular dysplasia, oligohydramnios, and neonatal renal failure. Spironolactone, used to treat primary aldosteronism and PCOS-related hyperaldosteronism, is also contraindicated in pregnancy due to antiandrogenic effects on the fetus. Women of reproductive age using spironolactone should use reliable contraception. If primary aldosteronism is diagnosed during pregnancy, surgical intervention is typically deferred until the postpartum period, and blood pressure is managed with calcium channel blockers or methyldopa, which have acceptable pregnancy safety profiles.

How to Get an Accurate PRA Result: Practical Preparation

Standardizing pre-test conditions is your best tool for a reliable result. These steps apply regardless of life stage.

Two to Four Weeks Before the Draw (If Clinically Safe)

Hold or switch medications that alter PRA where medically safe. Your prescribing clinician makes this call, not you. Specific washout periods:

• Spironolactone, eplerenone, amiloride: 4 weeks
• ACE inhibitors, ARBs, diuretics, beta-blockers: 2 weeks
• Oral contraceptives (if being evaluated for secondary hypertension): ideally 4 weeks, use barrier contraception during this window

Three Days Before

Maintain a normal sodium intake (3 to 5 grams per day). Do not fast. Avoid licorice-containing products.

Morning of the Test

Wake normally. Walk around or sit upright for two hours before the blood draw. The draw is typically done between 8 a.m. And 10 a.m. After the two-hour upright period. A simultaneous aldosterone sample is drawn from the same venipuncture. Note: some protocols require a separate supine sample taken after 30 to 60 minutes of lying flat; your ordering clinician will specify.

How to Lower or Raise PRA: The Clinical Context

Patients sometimes search for ways to shift their PRA number. The correct framing is: you do not want to manipulate PRA in isolation. You want to treat the underlying condition that is driving an abnormal PRA.

When PRA Is Pathologically High

Treatment targets the cause. Renal artery stenosis from fibromuscular dysplasia in a young woman responds to percutaneous transluminal angioplasty, which normalizes PRA by restoring renal perfusion. Volume depletion is corrected by addressing its source. Heart failure management with guideline-directed therapy (including ACE inhibitors or ARBs, which reduce angiotensin II and thereby allow PRA to rise reflectively while lowering the downstream harm) reduces the maladaptive RAAS activation.

From a lifestyle standpoint, higher dietary sodium modestly suppresses PRA, as does physical inactivity relative to sustained aerobic exercise (exercise acutely raises PRA). These are minor levers, not treatments.

When PRA Is Pathologically Low

If a low PRA with high aldosterone confirms primary aldosteronism, treatment is unilateral adrenalectomy for a unilateral adenoma (after adrenal vein sampling confirms lateralization) or mineralocorticoid receptor antagonist therapy (spironolactone or eplerenone) for bilateral hyperplasia. The SPARTACUS trial (2016) showed that adrenal vein sampling-guided surgery produced superior blood pressure and biochemical outcomes compared with empirical medical therapy in patients with unilateral disease. After surgical cure, PRA typically normalizes within months as the suppression is lifted.

Who Should Get a PRA Test: Life-Stage Guidance

Not every woman with high blood pressure needs a PRA draw. The Endocrine Society recommends screening in these groups:

• Hypertension with spontaneous or diuretic-induced hypokalemia
• Hypertension with an adrenal incidentaloma
• Resistant hypertension (blood pressure above goal on three drugs including a diuretic)
• Hypertension with a family history of early-onset hypertension or stroke before age 40
• Hypertension with a first-degree relative with primary aldosteronism
• New hypertension before age 40 in a woman (to rule out FMD and secondary causes)
• PCOS with hypertension or treatment-resistant blood pressure control

Women who do not need routine PRA screening: those with well-controlled blood pressure on one or two agents, no hypokalemia, and no adrenal mass found incidentally.

A 2020 ACOG practice bulletin on chronic hypertension in pregnancy emphasizes that evaluation for secondary hypertension causes, including aldosteronism, should ideally occur before conception or in the postpartum period, not during pregnancy, because diagnostic and treatment options are limited in gestation.

Evidence Gaps: What We Still Do Not Know About PRA in Women

Women have been under-represented in hypertension and adrenal research for decades. Several gaps remain real.

Most published ARR cutoffs were derived from mixed-sex cohorts that did not stratify results by menstrual cycle phase, OCP use, or menopausal status. A 2022 review in the Journal of the Endocrine Society called for sex-stratified reference intervals in primary aldosteronism screening specifically because of known hormonal effects on PRA. Until those sex-stratified ranges exist in widespread clinical use, results near a cutoff should be interpreted with extra caution in women whose hormonal status was not standardized at the time of testing.

The PCOS-RAAS connection is also under-studied. Most PCOS research has focused on androgens and insulin, with RAAS as a secondary variable. Whether treating insulin resistance in PCOS (with metformin or GLP-1 receptor agonists) normalizes PRA and ARR to a clinically meaningful degree remains an open question.